2 Top Biotech Stocks Defying the Bear Market
Last year was challenging for the stock market. Things have been better since 2023 started, but some equities have even performed pretty well throughout this ordeal. That's the case with Exelixis (NASDAQ: EXEL) and Axsome Therapeutics (NASDAQ: AXSM), two mid-cap biotech stocks. There are good reasons these drugmakers crushed the market since early 2022 and could continue doing so moving forward. Let's discuss why Exelixis and Axsome are solid picks for investors.
Source Fool.com
Exelixis Inc. Stock
€21.52
0.890%
With 20 Buy predictions and not the single Sell prediction the community is currently very high on Exelixis Inc..
With a target price of 26 € there is a positive potential of 20.82% for Exelixis Inc. compared to the current price of 21.52 €.
